-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Hennion & Walsh Asset Management Inc. Acquires 33,325 Shares of BeyondSpring Inc. (NASDAQ:BYSI)
Hennion & Walsh Asset Management Inc. Acquires 33,325 Shares of BeyondSpring Inc. (NASDAQ:BYSI)
Hennion & Walsh Asset Management Inc. increased its holdings in shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Rating) by 65.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,408 shares of the company's stock after buying an additional 33,325 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in BeyondSpring were worth $186,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Fox Run Management L.L.C. bought a new stake in shares of BeyondSpring during the 4th quarter worth $56,000. GSA Capital Partners LLP acquired a new position in BeyondSpring in the 4th quarter worth about $83,000. Alps Advisors Inc. acquired a new position in BeyondSpring in the 4th quarter worth about $205,000. Finally, BNP Paribas Arbitrage SA increased its holdings in BeyondSpring by 2,749.1% in the 4th quarter. BNP Paribas Arbitrage SA now owns 109,890 shares of the company's stock worth $498,000 after purchasing an additional 106,033 shares in the last quarter. 18.89% of the stock is currently owned by institutional investors.
Get BeyondSpring alerts:BeyondSpring Stock Up 1.3 %
Shares of BYSI opened at $1.60 on Friday. BeyondSpring Inc. has a 12-month low of $1.13 and a 12-month high of $33.00. The business has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $2.28. The stock has a market cap of $62.29 million, a PE ratio of -0.98 and a beta of 1.10.
BeyondSpring (NASDAQ:BYSI – Get Rating) last issued its earnings results on Thursday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. BeyondSpring had a negative return on equity of 144.52% and a negative net margin of 4,750.48%. The firm had revenue of $0.34 million during the quarter. On average, equities research analysts expect that BeyondSpring Inc. will post -0.95 EPS for the current year.BeyondSpring Profile
(Get Rating)
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
Want to see what other hedge funds are holding BYSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeyondSpring Inc. (NASDAQ:BYSI – Get Rating).
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
Hennion & Walsh Asset Management Inc. increased its holdings in shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Rating) by 65.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,408 shares of the company's stock after buying an additional 33,325 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in BeyondSpring were worth $186,000 at the end of the most recent reporting period.
据纳斯达克在提交给美国证券交易委员会的最新文件中称，该公司今年第一季度增持了65.2%的美团股票。该基金在本季度额外购买了33,325股后，持有84,408股该公司股票。截至上一次报告所述期间末，亨尼翁-沃尔什资产管理公司持有的万春医药股份价值18.6万美元。
Other institutional investors and hedge funds have also modified their holdings of the company. Fox Run Management L.L.C. bought a new stake in shares of BeyondSpring during the 4th quarter worth $56,000. GSA Capital Partners LLP acquired a new position in BeyondSpring in the 4th quarter worth about $83,000. Alps Advisors Inc. acquired a new position in BeyondSpring in the 4th quarter worth about $205,000. Finally, BNP Paribas Arbitrage SA increased its holdings in BeyondSpring by 2,749.1% in the 4th quarter. BNP Paribas Arbitrage SA now owns 109,890 shares of the company's stock worth $498,000 after purchasing an additional 106,033 shares in the last quarter. 18.89% of the stock is currently owned by institutional investors.
其他机构投资者和对冲基金也调整了对该公司的持股。福克斯奔跑管理有限公司在第四季度购买了价值56,000美元的万春医药新股。GSA Capital Partners LLP在第四季度收购了万春医药的一个新头寸，价值约83,000美元。阿尔卑斯顾问公司(Alps Advisors Inc.)在第四季度收购了万春医药的一个新头寸，价值约20.5万美元。最后，法国巴黎银行套利公司在第四季度增持了2,749.1%的万春医药。法国巴黎银行套利公司现在持有109,890股该公司股票，价值49.8万美元，上个季度又购买了106,033股。目前该公司18.89%的股份由机构投资者持有。
BeyondSpring Stock Up 1.3 %
万春医药股价上涨1.3%
Shares of BYSI opened at $1.60 on Friday. BeyondSpring Inc. has a 12-month low of $1.13 and a 12-month high of $33.00. The business has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $2.28. The stock has a market cap of $62.29 million, a PE ratio of -0.98 and a beta of 1.10.
上周五，比亚迪的股价开盘报1.60美元。万春医药股价跌至1.13美元的12个月低点和33.00美元的12个月高位。该业务的50日简单移动均线切入位在1.47美元，200日简单移动均线切入位在2.28美元。该股市值为6,229万美元，市盈率为-0.98，贝塔系数为1.10。
BeyondSpring Profile
万春医药简介
(Get Rating)
(获取评级)
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.
万春医药是一家临床期生物制药公司，与其子公司一起专注于癌症疗法的开发。该公司的主要资产是普利布林，这是一种选择性免疫调节微管结合剂，已经完成了预防化疗引起的中性粒细胞减少症和治疗晚期非小细胞肺癌的第三阶段临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
- 在新浪万春医药上免费获取斯托克新闻网的研究报告
- MarketBeat：回顾一周7/11-7/15
- Coupang的股票即将翻身吗？
- 你的投资组合中应该有这两家银行吗？
- Verint Systems Stock是一场客户互动活动
- 为什么Shopify股票拆分...并一如既往地适合购物
Want to see what other hedge funds are holding BYSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeyondSpring Inc. (NASDAQ:BYSI – Get Rating).
想看看其他对冲基金持有BYSI的哪些股份吗？访问HoldingsChannel.com获取万春医药的最新13F备案文件和内幕交易。(纳斯达克代码：BYSI-GET Rating)
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
接受万春医药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对万春医药及相关公司评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧